Recent Updates
Recently added Catalysts
AQST Positive Sentiment Score: 70/100

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Key Takeaway: Aquestive Therapeutics announced its participation in the Piper Sandler Spring Biopharma Symposium in Boston, scheduled for April 17. The company aims to engage with investors during this event, showcasing its innovative approaches to medicine. This engagement highlights the company's commitment to advancing its pharmaceutical developments. Additionally, the announcement includes forward-looking statements that indicate potential risks associated with its product development activities.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aquestive Therapeutics' management is actively participating in a prominent symposium.
  • The event facilitates investor engagement, which could enhance future investments.
  • The company's focus on innovative science and delivery technologies showcases its commitment to improving patient care.

Full Press Release Details

WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17.
About Aquestive Therapeutics, Inc.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Frequently Asked Questions

When will Aquestive participate in the Piper Sandler Symposium?

Aquestive will participate in the Piper Sandler Spring Biopharma Symposium on April 17.

What is the goal of Aquestive Therapeutics?

Aquestive aims to improve patients' lives through innovative science and delivery technologies.

What do forward-looking statements indicate?

Forward-looking statements express the company's expectations and are subject to risks.

Where can I find risk factors for Aquestive?

Risk factors are detailed in the company's Annual and Quarterly Reports filed with the SEC.

Last updated: Apr 9, 2025